Physician profile
Renuka Tunuguntla
NPI 1740401413
$513.65
in general payments reported to CMS, 2019-2025
15 companies · $69.79 in 2025
The $69.79 reported for 2025 was less than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.81 · 2021: $52.89 · 2022: $53.84 · 2023: $122 · 2024: $159 · 2025: $69.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $350.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $82.74 | 2021-2025 | Amyvid, Trulicity, Kisunla |
| Novartis Pharmaceuticals Corporation | $81.38 | 2019-2025 | |
| Boston Scientific Corporation | $60.24 | 2021-2022 | |
| Lundbeck LLC | $55.72 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $43.73 | 2023-2024 | Rexulti |
| Eisai INC. | $33.73 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $28.19 | 2024 | Lokelma, Farxiga |
| Ferring Pharmaceuticals INC. | $18.41 | 2023 | Rebyota |
| Teva Pharmaceuticals USA, INC. | $17.49 | 2025 | Austedo Xr |
| Acadia Pharmaceuticals INC | $17.32 | 2024 | Nuplazid |
| Collegium Pharmaceutical, INC. | $16.68 | 2024 | Xtampza |
| Janssen Pharmaceuticals, INC | $15.30 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.09 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.38 | 2019 | |
| Pfizer INC. | $13.25 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renuka Tunuguntla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.